IO INFORMATICS ADDS NEW MEMBERS TO ITS PERSONALIZED MEDICINE INFORMATICS WORKING GROUP
BERKELEY – DENVER – HOUSTON – GROTON – DUNDEE - PALO ALTO - VANCOUVER –
OAK RIDGE – MONTREAL – FREDERICK,
February 23, 2009.
IO Informatics, Inc. (“IOI” - www.io-informatics.com) today announced the addition of new members to its
Working Group on Informatics for Personalized Medicine.
Joining the group are Kathy Gibson (Helios Consulting), Uwe Christians (University of Colorado and Eurofins Medinet Denver), Herb Fritsche (MD Anderson)
and Dan Crowther (Wyeth). Each brings specific expertise and unique experiences to the working group’s, contributing to the breadth and
depth of the
group’s current membership: Jack Collins (NCI SAIC), Amar Das (Stanford), Erich Gombocz (IO Informatics), William Hayden (IO Informatics), Bruce McManus
(PROOF), Robert Stanley (IO Informatics) and David Stanley (Vascular Diagnostic Center Oak Ridge) in a group that brings together worldwide experts with scientific,
practical and business experience in informatics, healthcare and life sciences research areas.
“We are very pleased to add four new members to our Personalized Medicine Working Group, and deeply appreciate each group members’ contribution
to the advancement of IO Informatics’ Sentient software suite. Together the contributions of all our members are helping us achieve our mandate to deliver
on the life-changing promise of informatics for predictive biology and personalized medicine” stated Robert Stanley, President and CEO of IOI.
The members of the new Working Group are:
Uwe Christians, MD, PhD: He received his M.D. and his Ph.D. in Experimental and Clinical Pharmacology and Toxicology from the
Medizinische Hochschule Hannover, Hannover, Germany, where he is a board-certified pharmacologist, toxicologist and clinical pharmacologist. Dr. Christians
holds two faculty appointments, one as Professor in the Department of Anesthesiology and the other as Professor (apl.) in the Department of Pharmacology,
Medizinische Hochschule Hannover in Germany. In addition, he is the Director of the Clinical Nutrition Research Unit Mass Spectrometry Core at the University
of Colorado. His main research interests are the development of translational strategies and novel concepts for drug development, pharmaco-/ toxicodynamic
therapeutic drug monitoring and personalized medicine. The focus of his work is how to use proteo-metabonomic strategies to discover, qualify and develop
novel and simple, practicable combinatorial molecular markers, diagnostic and monitoring strategies. These technologies are also offered as contract research
through Eurofins Medinet Denver.
Dan Crowther PhD: Head of Informatics for the Translational Medicine Research Collaboration. The TMRC is a unique collaboration involving
4 Scottish universities, 4 NHS trusts, Scottish Enterprise and Wyeth which aims to develop a network of clinical and scientific excellence throughout Scotland
in order to discover and develop biomarkers. Dr Crowther received his degree in Biochemistry and his PhD in Molecular Biology from Oxford University. Prior to
joining Wyeth, he worked at GlaxoSmithKline and its legacy companies for 9 years where he managed a team of computational biologists within the
Herbert Fritsche PhD: Dr. Herbert Fritsche is Professor and Chief of the Clinical Chemistry Laboratory in the Department of Laboratory
Medicine at the University of Texas M. D. Anderson Cancer Center in Houston, TX. In addition, he conducts an active research program in the development
and validation of cancer diagnostics. Currently, he is a member of the editorial board of six scientific journals, a Fellow in the National Academy of Clinical
Biochemistry (NACB), a member of the Tumor Marker Expert Panel (American Society of Clinical Oncology), the Tumor Marker Guidelines Committee for NACB,
the Technology Expert Panel for Blue Cross Blue Shield, and he is an active member of three professional societies. He has published more than 180 manuscripts
and 30 book chapters in the field of cancer diagnostics, is a member of the scientific advisory boards for seven diagnostic companies, and holds four patents
and one patent application.
Kathy Gibson: President and Founder of Helio Consulting, Inc. Helio is a leading management and technology consulting company focusing
on helping academia, government and corporate clients achieve growth objectives and move through significant transitions in their business or operating
environment. Prior to forming Helio, Kathy spent thirteen years with Pfizer, Inc as Vice President of Corporate Business Development and Innovation and also
as Vice President and CIO for worldwide Research Informatics.
About IO Informatics
IO Informatics is at the forefront of a global revolution in software methods for data integration. IO Informatics’ Sentient suite of software products enables
biotechnology, pharmaceutical, medical and other life science researchers to structure and define complex data relationships, view these relationships, query
them, and capitalize on them — all within a secure, compliant, auditable framework that helps organizations accumulate and leverage knowledge. Founded in
2003, IO Informatics is headquartered in Berkeley, California ((www.io-informatics.com)).